Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.35 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.34 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31561697 | 0.80 | L3MBTL1 (0.45) | L3MBTL1ALDH1A1MAPK1SMN1; SMN2KDM4E | |
| SCHEMBL7050570 | 0.80 | L3MBTL1 (0.45) | L3MBTL1ALDH1A1MAPK1SMN1; SMN2KDM4E | |
| SCHEMBL22011492 | 0.79 | TSHR (0.46) | L3MBTL1ALDH1A1MAPK1SMN1; SMN2CYP2D6 | |
| SCHEMBL26916320 | 0.79 | TSHR (0.46) | L3MBTL1ALDH1A1MAPK1SMN1; SMN2CYP2D6 | |
| Hydrochloric Acid SCHEMBL1670845 | 0.77 | TSHR (0.45) | L3MBTL1ALDH1A1MAPK1SMN1; SMN2CYP2D6 | |
| SCHEMBL1666944 | 0.76 | ACP3 (0.42) | ALDH1A1CYP2D6KDM4ELMNAADRA2A | |
| SCHEMBL28459741 | 0.75 | SRC (0.45) | L3MBTL1ALDH1A1MAPK1SMN1; SMN2CYP2D6 | |
| SCHEMBL1667056 | 0.75 | GAA (0.45) | ALDH1A1SMN1; SMN2CYP2D6GAATSHR | |
| SCHEMBL1667434 | 0.75 | CYP2D6 (0.41) | ALDH1A1CYP2D6KDM4EGAALMNA | |
| SCHEMBL1669592 | 0.75 | CYP1A2 (0.47) | ALDH1A1CYP2D6LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011038469-A1 | SUPPRESSIVE AGENTS | PRINCE HENRY'S INSTITUTE OF MEDICAL RESEARCH (AU) | 2011-04-07 | — | — | WO | disclosed |
| WO-2010088729-A1 | COMPOSITIONS AND USES THEREFOR | UNIVERSITY OF TASMANIA THROUGH THE MENZIES RESEARCH INSTITUTE (AU) | 2010-08-12 | — | — | WO | disclosed |
| WO-2010022444-A1 | METHODS AND AGENTS FOR MODULATING KINASE SIGNALLING PATHWAYS THROUGH MODULATION OF MIXED-LINEAGE KINASE DOMAIN-LIKE PROTEIN (MLKL) | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2010-03-04 | — | — | WO | disclosed |
| US-20090215669-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETES | DIA-B TECH LIMITED (AU) | 2009-08-27 | — | — | US | disclosed |
| WO-2009021289-A1 | POTASSIUM CHANNEL INHIBITORS | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2009-02-19 | — | — | WO | disclosed |
| EP-1962882-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETES | Dia-B Tech Limited (AU) | 2008-09-03 | — | — | EP | disclosed |
| WO-2008025069-A1 | METHODS OF MODULATING CELLULAR ACTIVITY AND COMPOSITIONS THEREFOR | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2008-03-06 | — | — | WO | disclosed |
| US-20070197430-A1 | Conjugates And Therapeutic Uses Thereof | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2007-08-23 | — | — | US | disclosed |
| WO-2007059569-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETES | DIA-B TECH LIMITED (AU) | 2007-05-31 | — | — | WO | disclosed |
| EP-1781689-A1 | CONJUGATES AND THERAPEUTIC USES THEREOF | The Walter and Eliza Hall Institute of Medical Research (AU) | 2007-05-09 | — | — | EP | disclosed |
| WO-2007025332-A1 | A PEPTIDE AND ZINC ION COMPOSITION FOR TREATING DIABETES AND ENHANCING IMMUNE FUNCTION | DIA-B TECH LIMITED (AU) | 2007-03-08 | — | — | WO | disclosed |
| US-20070032417-A1 | Peptides and therapeutic uses thereof | WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2007-02-08 | — | — | US | disclosed |
| WO-2006000034-A1 | CONJUGATES AND THERAPEUTIC USES THEREOF | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2006-01-05 | — | — | WO | disclosed |
| WO-2004058804-A1 | PEPTIDES AND THERAPEUTIC USES THEREOF | WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032417-A1 | Peptides and therapeutic uses thereof | BCL2, BAX, BCL2L13 | L3MBTL1 114/4885ALDH1A1 4834/4885MAPK1 3310/4885 |
| US-20070197430-A1 | Conjugates And Therapeutic Uses Thereof | BCL2, BAX, BAD | L3MBTL1 110/4885ALDH1A1 4519/4885MAPK1 3871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.